Short communicationPublished 18 Sep 2020
Bullous pemphigoid in a psoriatic patient after adalimumab therapy: Remission with ustekinumab
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Bullous pemphigoid (BP) is an acquired autoimmune blistering disease affecting especially the elderly. Among drugs implicated in BP pathogenesis, anti TNFa agents have been reported as inducing agents. Ustekinumab is a monoclonal antibody that targets the IL-12/23 receptor and is approved for treating moderate to severe psoriasis. Coexistence of BP and psoriasis represents a therapeutic challenge. We report a 52 year old male patient with psoriasis who developed BP after treated with adalimumab. Long term remission of both cutaneous diseases was achieved after administration of ustekinumab. In our knowledge, this is the second case of completely resolution of BP and psoriasis with monoclonal IL-12/23 agent.
Keywords
Subjects
SurgeryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Perioperative Medicine
- SubjectSurgery
- BylineArticles whose byline prints “A Papadopoulou”
- BylineArticles whose byline prints “AV RoussakiSchultze”
- BylineArticles whose byline prints “E Zafiriou”
